Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.08
MDCO's Cash to Debt is ranked higher than
66% of the 1173 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. MDCO: 1.08 )
MDCO' s 10-Year Cash to Debt Range
Min: 1.08   Max: No Debt
Current: 1.08

Equity to Asset 0.44
MDCO's Equity to Asset is ranked higher than
57% of the 983 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. MDCO: 0.44 )
MDCO' s 10-Year Equity to Asset Range
Min: 0.44   Max: 0.89
Current: 0.44

0.44
0.89
F-Score: 3
Z-Score: 1.32
M-Score: -3.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -13.51
MDCO's Operating margin (%) is ranked higher than
53% of the 1117 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. MDCO: -13.51 )
MDCO' s 10-Year Operating margin (%) Range
Min: -401.44   Max: 14.87
Current: -13.51

-401.44
14.87
Net-margin (%) -3.29
MDCO's Net-margin (%) is ranked higher than
56% of the 1117 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.55 vs. MDCO: -3.29 )
MDCO' s 10-Year Net-margin (%) Range
Min: -385.2   Max: 29.79
Current: -3.29

-385.2
29.79
ROE (%) -2.39
MDCO's ROE (%) is ranked higher than
59% of the 1157 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.46 vs. MDCO: -2.39 )
MDCO' s 10-Year ROE (%) Range
Min: -237.8   Max: 35
Current: -2.39

-237.8
35
ROA (%) -1.16
MDCO's ROA (%) is ranked higher than
60% of the 1183 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.53 vs. MDCO: -1.16 )
MDCO' s 10-Year ROA (%) Range
Min: -183.56   Max: 24.65
Current: -1.16

-183.56
24.65
ROC (Joel Greenblatt) (%) -113.45
MDCO's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 1178 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.83 vs. MDCO: -113.45 )
MDCO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -16443.26   Max: 300.56
Current: -113.45

-16443.26
300.56
Revenue Growth (3Y)(%) 8.10
MDCO's Revenue Growth (3Y)(%) is ranked higher than
76% of the 971 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. MDCO: 8.10 )
MDCO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 88.9
Current: 8.1

0
88.9
EBITDA Growth (3Y)(%) -52.10
MDCO's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. MDCO: -52.10 )
MDCO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -7.9
Current: -52.1

» MDCO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MDCO Guru Trades in Q2 2014

George Soros 75,000 sh (New)
Joel Greenblatt 194,954 sh (New)
Chuck Royce 6,656,025 sh (+8.84%)
Chuck Royce 6,571,800 sh (+7.47%)
Vanguard Health Care Fund 4,700,058 sh (unchged)
Jim Simons Sold Out
John Hussman Sold Out
RS Investment Management 484,842 sh (-7.43%)
» More
Q3 2014

MDCO Guru Trades in Q3 2014

Vanguard Health Care Fund 4,762,730 sh (+1.33%)
Chuck Royce 6,729,175 sh (+1.10%)
George Soros Sold Out
RS Investment Management 477,466 sh (-1.52%)
Joel Greenblatt 24,009 sh (-87.68%)
» More
Q4 2014

MDCO Guru Trades in Q4 2014

Steven Cohen 221,600 sh (New)
Vanguard Health Care Fund 5,461,430 sh (+14.67%)
Joel Greenblatt Sold Out
RS Investment Management 476,998 sh (-0.10%)
Chuck Royce 4,647,740 sh (-30.93%)
Chuck Royce 4,647,740 sh (-30.93%)
» More
Q1 2015

MDCO Guru Trades in Q1 2015

Paul Tudor Jones 9,000 sh (New)
Steven Cohen 273,500 sh (+23.42%)
Vanguard Health Care Fund 5,564,220 sh (+1.88%)
RS Investment Management 338,358 sh (-29.07%)
Chuck Royce 2,081,370 sh (-55.22%)
» More
» Details

Insider Trades

Latest Guru Trades with MDCO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 37.59
MDCO's Forward P/E is ranked higher than
73% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MDCO: 37.59 )
N/A
P/B 1.80
MDCO's P/B is ranked higher than
85% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. MDCO: 1.80 )
MDCO' s 10-Year P/B Range
Min: 1.14   Max: 9.94
Current: 1.8

1.14
9.94
P/S 2.62
MDCO's P/S is ranked higher than
74% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. MDCO: 2.62 )
MDCO' s 10-Year P/S Range
Min: 0.9   Max: 13.29
Current: 2.62

0.9
13.29
POCF 52.78
MDCO's POCF is ranked higher than
74% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.21 vs. MDCO: 52.78 )
MDCO' s 10-Year POCF Range
Min: 8.63   Max: 296.67
Current: 52.78

8.63
296.67
EV-to-EBIT -19.10
MDCO's EV-to-EBIT is ranked higher than
57% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.19 vs. MDCO: -19.10 )
MDCO' s 10-Year EV-to-EBIT Range
Min: -824.5   Max: 790.2
Current: -19.1

-824.5
790.2
Shiller P/E 42.20
MDCO's Shiller P/E is ranked higher than
83% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MDCO: 42.20 )
MDCO' s 10-Year Shiller P/E Range
Min: 25.91   Max: 748.5
Current: 42.2

25.91
748.5
Current Ratio 2.51
MDCO's Current Ratio is ranked higher than
74% of the 1051 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.20 vs. MDCO: 2.51 )
MDCO' s 10-Year Current Ratio Range
Min: 0.75   Max: 10.09
Current: 2.51

0.75
10.09
Quick Ratio 2.15
MDCO's Quick Ratio is ranked higher than
77% of the 1051 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. MDCO: 2.15 )
MDCO' s 10-Year Quick Ratio Range
Min: 0.75   Max: 9.44
Current: 2.15

0.75
9.44
Days Inventory 130.90
MDCO's Days Inventory is ranked higher than
72% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 145.57 vs. MDCO: 130.90 )
MDCO' s 10-Year Days Inventory Range
Min: 15.56   Max: 1606.52
Current: 130.9

15.56
1606.52
Days Sales Outstanding 53.87
MDCO's Days Sales Outstanding is ranked higher than
85% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 91.38 vs. MDCO: 53.87 )
MDCO' s 10-Year Days Sales Outstanding Range
Min: 26.9   Max: 156.75
Current: 53.87

26.9
156.75

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.60
MDCO's Price/DCF (Projected) is ranked higher than
92% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MDCO: 1.60 )
MDCO' s 10-Year Price/DCF (Projected) Range
Min: 0.84   Max: 11.15
Current: 1.6

0.84
11.15
Price/Median PS Value 0.90
MDCO's Price/Median PS Value is ranked higher than
90% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. MDCO: 0.90 )
MDCO' s 10-Year Price/Median PS Value Range
Min: 0.35   Max: 65.44
Current: 0.9

0.35
65.44
Earnings Yield (Greenblatt) -5.30
MDCO's Earnings Yield (Greenblatt) is ranked lower than
52% of the 1170 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. MDCO: -5.30 )
MDCO' s 10-Year Earnings Yield (Greenblatt) Range
Min: -5.3   Max: 15.2
Current: -5.3

-5.3
15.2
Forward Rate of Return (Yacktman) -16.37
MDCO's Forward Rate of Return (Yacktman) is ranked higher than
56% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.55 vs. MDCO: -16.37 )
MDCO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -16.6   Max: 5.2
Current: -16.37

-16.6
5.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:MZN.Germany,
The Medicines Company was incorporated in Delaware on July 31, 1996. The Company is a global biopharmaceutical company focused on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on 3,000 acute and intensive care hospitals worldwide. The Company markets products including; Angiomax (bivalirudin), Recothrom Thrombin, topical (Recombinant), Cleviprex (clevidipine) injectable emulsion and Minocin IV (Minocycline for Injection). Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound. Recothrom is a surgical hemostat that is applied topically during surgery to stop bleeding. Cleviprex is an intravenous small molecule calcium channel blocker. Minocin IV is an Tetracycline-class antibiotic used for treatment of bacterial infections caused by Acinetobacter species. The Company has a pipeline of acute and intensive care hospital products in development, including five registration stage product candidates; cangrelor, oritavancin, IONSYSTM (fentanyl iontophoretic transdermal system), Fibrocaps and RPX-602, and three research and development product candidates, MDCO-216, CarbavanceTM and ALN-PCSsc. In addition to these products and product candidates company also sells a ready-to-use formulation of Argatroban and have a portfolio of ten generic drugs, referred to as acute care generic products, that have the non-exclusive right to market in the United States. The Company is currently selling three of its acute care generic products, midazolam, ondansetron and rocuronium; and also co-promote the oral tablet antiplatelet medicine BRILINTA (ticagrelor) in the United States as part of global collaboration agreement with AstraZeneca LP and the Boston Scientific Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, or the Promus PREMIER Stent System, in the United States under its co-promotion agreement with Boston Scientific Corporation, or BSX. It faces competition from pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. The Company and its customers are subject to extensive regulation by the federal government, and the governments of the states and foreign countries in which it may conduct its business. In addition to regulations in the United States, the Company is subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of its products.
» More Articles for MDCO

Headlines

Articles On GuruFocus.com
Netflix Profit Above Consensus, Panera Bread Boosts Buyback Plan, Medicines Co Cangrelor Well-Recomm Apr 16 2015 
Chuck Royce Buys Stifel Financial, Tidewater, Alamos, Sells Kennametal, Gardner Denver, Gartner Apr 25 2013 
Weekly CFO Sells Highlight: BK, MDCO, EBAY, MS, PHMD Jan 27 2013 
Weekly CFO Sells Highlight: MDCO, SIG, VCI, PHMD, SNPS Jan 21 2013 
George Soros' Top Buys in the Last Quarter Dec 23 2011 
George Soros Buys Amazon.com Inc., Motorola Solutions, Sandisk, Sells Ralph Lauren, Dendreon, Lawson Nov 15 2011 
Medicines Company (MDCO) Chairman & CEO Clive Meanwell sells 100,000 Shares Mar 01 2011 
Medicines Company Reports Operating Results (10-Q) Nov 09 2010 
Medicines Company Reports Operating Results (10-Q) May 10 2010 
Medicines Company (MDCO) Chairman & CEO Clive Meanwell sells 181,500 Shares May 04 2010 

More From Other Websites
The Medicines Company to participate in the Jefferies 2015 Healthcare Conference May 22 2015
The Medicines Company to participate in the Jefferies 2015 Healthcare Conference May 22 2015
10-Q for The Medicines Co. May 07 2015
The Medicines Company to Participate in Bank of America Merrill Lynch 2015 Health Care Conference May 07 2015
The Medicines Company to Participate in Bank of America Merrill Lynch 2015 Health Care Conference May 07 2015
The Medicines Co. Incurs Loss in Q1, Angiomax Sales Fall - Analyst Blog May 06 2015
Medicines Co Earnings Call scheduled for 8:30 am ET today May 05 2015
The Medicines Company Reports First Quarter 2015 Financial Results and Operational Developments May 05 2015
MEDICINES CO /DE Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 05 2015
Medicines Co. misses 1Q revenue forecasts May 05 2015
Medicines Co. misses 1Q revenue forecasts May 05 2015
The Medicines Company Reports First Quarter 2015 Financial Results and Operational Developments May 05 2015
Q1 2015 Medicines Co Earnings Release - Before Market Open May 05 2015
BUZZ-U.S. STOCKS ON THE MOVE-LinkedIn, Tesla, Lloyds, CVS Health May 01 2015
FDA approves the Medicines Co's pain drug device Ionsys Apr 30 2015
The Medicines Company Announces FDA Approval of IONSYS® (fentanyl iontophoretic transdermal system)... Apr 30 2015
The Medicines Company Announces FDA Approval of RAPLIXA™ (Fibrin Sealant), the First and Only... Apr 30 2015
The Medicines Company Announces FDA Approval of RAPLIXA™ (Fibrin Sealant), the First and Only... Apr 30 2015
U.S. FDA approves the Medicines Co's pain drug device Ionsys Apr 30 2015
The Medicines Company Announces FDA Approval of IONSYS® (fentanyl iontophoretic transdermal system)... Apr 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK